Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,474 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,543 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00068003 | Harvesting Cells for Experimental Cancer Treatments | enrolling by invitation | — | 7,000 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT00071045 | Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members | enrolling by invitation | — | 6,000 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 28, 2026 |
| clinicaltrials |
| NCT02473757 | Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies | enrolling by invitation | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03762733 | Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies | enrolling by invitation | — | 500 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06472817 | Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant Men | enrolling by invitation | — | 80 | Mayo ClinicOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07328516 | Natural History Study of Early Life Exposures in Agriculture (ELEA) | enrolling by invitation | — | 64,277 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07844460 | 3D MRE-Based Evaluation of Vestibular Schwannoma Mechanical Properties and Histological Features | enrolling by invitation | — | 30 | Shengjing HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01727284 | MR-Guided Cryoablation of Prostate Bed Recurrences | enrolling by invitation | N/A | 200 | Mayo ClinicOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06788509 | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring | enrolling by invitation | Phase 1 | 120 | Janssen Research & Development, LLCINDUSTRY | 15 | Sep 25, 2026 | clinicaltrials |
| NCT06936527 | XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation(XS-03-II201) | enrolling by invitation | Phase 1 / Phase 2 | 102 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06208878 | A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies | enrolling by invitation | — | 70 | CRISPR Therapeutics AGINDUSTRY | 4 | Sep 24, 2026 | clinicaltrials |
| NCT07838519 | Personalizing Veterans' Lung Cancer Screening and Diagnosis(MAS-EXPAND) | enrolling by invitation | N/A | 1,400 | VA Office of Research and DevelopmentFED | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07344220 | Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate(DZ-002-201) | enrolling by invitation | Phase 2 | 39 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03226704 | Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing | enrolling by invitation | — | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03628612 | Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells | enrolling by invitation | Phase 2 | 500 | Autolus LimitedINDUSTRY | 3 | Sep 22, 2026 | clinicaltrials |
| NCT04266093 | Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies | enrolling by invitation | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07832396 | Community Study to Increase Mammogram Screening Among Overdue Women(IMPLEMENT) | enrolling by invitation | N/A | 15,000 | National University Hospital, SingaporeOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07833852 | Long-Term Immune Persistence After Bivalent HPV Vaccination in Females From Study 311-HPV-1005 | enrolling by invitation | — | 486 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04291755 | Development and Analysis of a Stool Bank for Cancer Patients | enrolling by invitation | — | 100 | Persephone BiosciencesINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06714084 | CNCMT：a Multi-center, Prospective, Single-arm Study(CNCMT) | enrolling by invitation | N/A | 20 | Hubei Cancer HospitalOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06987058 | RVU120 Rollover Study(ROVER-01) | enrolling by invitation | Phase 2 | 14 | Ryvu Therapeutics SAINDUSTRY | 2 | Sep 17, 2026 | clinicaltrials |
| NCT02526797 | Multiparametric MRI in Men With Prostate Cancer Undergoing Active Surveillance | enrolling by invitation | — | 150 | Herlev HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03648359 | Multiparametric MRI in Men With Prostate Cancer Enrolled in Active Surveillance | enrolling by invitation | N/A | 200 | Herlev HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06080113 | Cancer of the Prostate Treated With Focal Implantation of a RadioactivE Source(CAPFIRE) | enrolling by invitation | N/A | 50 | Herlev HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07822815 | Difficult Airway Management in Oncology: An International Delphi Consensus Study (DAMO)(DAMO) | enrolling by invitation | — | 40 | Onco Critical Care SocietyOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07690306 | Development and Validation of a Non-Invasive AI Diagnostic Model for Prostate Cancer Using Multiparametric MRI and PSMA PET/CT | enrolling by invitation | — | 1,500 | Xiangya Hospital of Central South UniversityOTHER | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07775209 | Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma(SSIBLING) | enrolling by invitation | Phase 2 | 24 | University of Vermont Medical CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07168486 | CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas | enrolling by invitation | Phase 1 | 15 | University of Maryland, BaltimoreOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07103863 | Multimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis Prognosis(AL-CA) | enrolling by invitation | — | 49 | Beijing Anzhen HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07813390 | Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure(HLA-AML) | enrolling by invitation | Phase 2 | 73 | Guangdong Second Provincial General HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06767891 | Real-world Study of Acalabrutinib(RESA) | enrolling by invitation | — | 160 | Ruijin HospitalOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07059819 | Local Hyperthermia for the Treatment of Cervical Persistent High-risk Infection | enrolling by invitation | N/A | 400 | First Hospital of China Medical UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05645536 | Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study | enrolling by invitation | Phase 3 | 250 | Tolmar Inc.INDUSTRY | 6 | Sep 1, 2026 | clinicaltrials |
| NCT07798466 | Immediate Autologous Tissue Breast Reconstruction and Radiotherapy Strategy After Breast Cancer Surgery | enrolling by invitation | — | 128 | Fudan UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06515860 | Neurofibromatosis Type 1 Tumor Early Detection Study(NF1-TED) | enrolling by invitation | — | 1,000 | David MillerOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT00923026 | Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies | enrolling by invitation | — | 1,150 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07078409 | Clinician Nudge to Referral of Adnexal Masses to Gynecologic Oncology | enrolling by invitation | N/A | 240 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07642401 | Large-scale Models of Esophageal Cancer and Related Research(DeepDT) | enrolling by invitation | — | 12,000 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07180121 | Information Needs and Supportive Rehabilitation Over Time in Patients Undergoing Cystectomy in Bladder Cancer(CaRe) | enrolling by invitation | — | 200 | Linkoeping UniversityOTHER_GOV | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07784660 | Molecular Imaging of EpCam Expression in Breast Cancer Using [99mTc]Tc-DARPinEc1-G3C(EpCam-Scan) | enrolling by invitation | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07784309 | A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies | enrolling by invitation | Phase 1 | 13 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06872619 | RegisterPROS - A Registry for Prostate Cancers(RegisterPROS) | enrolling by invitation | — | 1,000 | Wren Laboratories LLCINDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07338968 | A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma(CoMpass) | enrolling by invitation | — | 100 | Aura BiosciencesINDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT02609269 | Decipher Genomics Resource for Intelligent Discovery(GRID®) | enrolling by invitation | — | 1,000,000 | GenomeDx Biosciences CorpINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT06184594 | Evaluating the Efficacy of the eNav Toolkit to Improve Colorectal Cancer Screening | enrolling by invitation | N/A | 400 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06910072 | Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC）(UPGRADE-TNBC) | enrolling by invitation | Phase 2 / Phase 3 | 32 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07620574 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | enrolling by invitation | Phase 3 | 5,000 | ExelixisINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05650749 | GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma(GPC2) | enrolling by invitation | Phase 1 | 45 | Stephan Grupp MD PhDOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT01728402 | Pathogenesis of Hematologic Malignancies | enrolling by invitation | — | 5,000 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02759744 | Fusion Guided Focal Laser Ablation of Prostate Cancer | enrolling by invitation | N/A | 30 | National Institutes of Health Clinical Center (CC)NIH | 1 | Aug 13, 2026 | clinicaltrials |
Data updated 21 hours agoSource updated Sep 28, 2026source: clinicaltrials